Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Cell Carcinoma: early-phase trial registry
50 of 122 indexed Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #100 of 28,707 conditions by registered trial count.
122 US clinical trials · 50 currently recruiting · #100 of 28,707 conditions by registered trial count
Renal Cell Carcinoma: 122 US clinical trials tracked, 50 recruiting.
Renal Cell Carcinoma is the subject of 122 registered US clinical trials on ClinicalTrials.gov, 50 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 90 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition renal-cell-carcinoma
OPEN 50 | RECR 41% | LATE 10 | EARLY 90 | RANK #100 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Ovarian Neoplasms (41% recruiting · 39 trials)
Renal Cell Carcinoma lists 50 open slots (41% of 122 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Cell Carcinoma is recruiting above its size-band peers.
50 of 122 indexed trials (41%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Renal Cell Carcinoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 7 of 122 trials (5.7%). 87 distinct sponsors appear on at least one study for this condition label.
-
Typical Renal Cell Carcinoma enrolment sits around 80 participants.
Median target enrolment is 80 among the 122 trials that report a genuine target (sentinel values excluded). 69 of those (56.6%) plan for fewer than 100 participants.
-
Renal Cell Carcinoma research is mostly interventional.
110 interventional and 12 observational studies make up this index (90.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
122 total, page 3 of 3
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics
NCT02526017
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
NCT01472081
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Hoosier Cancer Research Network
NCT01034631
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor
NCT03517488
Renal Mass Registry
Mayo Clinic
NCT01887574
Phase I Biomarker Study (BMS-936558)
Bristol-Myers Squibb
NCT01358721
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Idera Pharmaceuticals
NCT00729053
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT00918281
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Thomas Jefferson University
NCT02440334
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT03207347
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Moshe Ornstein
NCT02762006
A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
Astellas Pharma
NCT01114230
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
University of Colorado, Denver
NCT00353301
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Argos Therapeutics
NCT00678119
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford University
NCT04508725
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
Argos Therapeutics
NCT00272649
Sorafenib and RAD001 Renal Cell Carcinoma
University of California, San Francisco
NCT00384969
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
University of Kansas
NCT01173445
Study of CP-461 in Patients With Advanced Renal Cell Cancer
Astellas Pharma
NCT00036036
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT03758781
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
Daniel George, MD
NCT00788060
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 51 |
| Phase 2 | 39 |
| Phase 3 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Cell Carcinoma page
122 registered trials, 50 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 50 Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Cell Carcinoma condition card totals 122 registered trials; most-linked intervention Nivolumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.